Navigation Links
Widespread Acceptance and Use of Accuray's Technologies Continue to Grow
Date:11/25/2013

SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than half a million patients, further positioning the company as a leader in precise, innovative radiation oncology. To date, the CyberKnife and TomoTherapy Systems have been used in 40 countries to treat patients across the full spectrum of radiation oncology cases including prostate, lung, liver, breast and head and neck cancers.

"The CyberKnife and TomoTherapy Systems are widely recognized by the global oncology community as leading edge, innovative treatment solutions," said Joshua H. Levine, president and chief executive officer of Accuray. "These installation and patient milestones reflect our Systems' continued and growing adoption across the world. Though we are proud of these achievements, there are many more patients that could benefit from the personalized, non-invasive treatment options our technologies provide. We will continue our commitment to maximizing patient access and coverage, while working toward a future where the fear, pain and suffering of cancer are a thing of the past."

"With the ability to image my patients every day I can create highly conformal treatment plans that are more specific to the tumor and can be delivered in fewer doses, thus allowing me to treat indications ranging from breast, liver, pancreatic and head and neck cancers," said Martin Keisch, M.D., president and medical director at Cancer Healthcare Associates in Miami, Florida. "We went live with our TomoTherapy System in December 2012. We have treated more than 200 patients and our system has not been down for more than one hour. The TomoTherapy System has redefined how I deliver radiation treatment."

Accuray's newest innovations are the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems treatment solutions. Between them the entire spectrum of radiation therapy needs are covered. The CyberKnife M6 Series offers the ability to deliver high-quality, high-dose distributions that can be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The TomoTherapy H Series facilitates interactive treatment planning for clinicians to make development of customized plans for a wide range of patients and disease types efficient. The innovative design of the System allows treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to adoption of new technologies, number of patients treated, clinical experience, clinical applications, clinical results, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
2. Leader In At-Home Laboratory Testing Praises Federal Panels Recommendations For Widespread HIV Testing
3. Frost & Sullivan: Digitisation of Australias healthcare system met with widespread apprehension
4. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
5. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
6. United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
7. China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of Compliance by NYSE MKT LLC
8. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Acceptances Announcement
11. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):